+

WO1999047117A1 - Compositions d'humidification de la peau - Google Patents

Compositions d'humidification de la peau Download PDF

Info

Publication number
WO1999047117A1
WO1999047117A1 PCT/US1999/005413 US9905413W WO9947117A1 WO 1999047117 A1 WO1999047117 A1 WO 1999047117A1 US 9905413 W US9905413 W US 9905413W WO 9947117 A1 WO9947117 A1 WO 9947117A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
vitamin
mixtures
compound
group
Prior art date
Application number
PCT/US1999/005413
Other languages
English (en)
Inventor
Donald Lynn Bissett
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to CA002323101A priority Critical patent/CA2323101A1/fr
Priority to BR9907944-5A priority patent/BR9907944A/pt
Priority to KR1020007010163A priority patent/KR20010041868A/ko
Priority to EP99911343A priority patent/EP1063965A1/fr
Priority to AU30006/99A priority patent/AU3000699A/en
Priority to JP2000536357A priority patent/JP2002506805A/ja
Publication of WO1999047117A1 publication Critical patent/WO1999047117A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to methods of improving skin moisturization or skin hydration, and more specifically, to methods improving the skin's absorptive and/or adsorptive capacity for water.
  • the skin is composed of an external cellular layer called the stratum corneum, an underlying epidermal layer and the dermis.
  • stratum corneum which varies in thickness from approximately 15 microns on the face and the backs of the hands to 500 microns on the soles of the feet and the palms of the hands, plays a significant role in controlling the level of moisture in the skin. It is composed of keratinized cells, a natural moisturizing factor and lipids. All of these function together as a protective coating, as well as a moisture barrier to retain moisture within the skin.
  • the cells of the skin undergo change from normal living cell structure to the keratinized layer of the corneum.
  • some proteins particularly involucrin, are crosslinked to become the envelop of the stratum corneum cell.
  • These cells contain keratins, which are also produced in the epidermis, and when hydrated function to provide flexibility to the stratum corneum.
  • Other proteins, particularly filaggrin, are broken down to products which are located in the stratum corneum cells and function as natural moisturizing compounds.
  • Below the epidermal layer lies the normal dermis of the skin, which holds and transports water to the epidermal area.
  • the level of moisture in the skin is dependent upon a number of factors. Among these factors are the water binding potential of the stratum corneum, the rate at which water is supplied to the internal layers of the stratum corneum, and the rate at which water is lost from the external surface of the skin. With these factors in mind, investigators have, for a number of years, been actively searching for ways to maintain such proper levels of moisture in the skin.
  • Occlusives are hydrophobic substances that promote water retention by forming a barrier on the skin that will prevent moisture loss.
  • the most commonly used occlusive agents include petrolatum, lanolin, cocoa butter, mineral oil and silicones.
  • Nitamin B 3 compounds are effective in providing moisture or hydration to the skin by improving the adsorption of water onto stratum corneum or the absorption of water into stratum corneum.
  • Vitamin B 3 compounds improve the production of the stratum corneum cell envelop, stratum corneum keratins, natural moisturizing factor precursor (filaggrin), and natural moisturizing factors which promote the skin's ability to take up and bind water.
  • Another object of the present invention is to provide methods of improving the skin's adsorptive and/or absorptive capacity for water by applying a safe and effective amount of a composition containing a vitamin B 3 compound.
  • the present invention relates to methods of moisturizing or hydrating the skin by improving the adsorption of water to, and/or improving the absorptive capacity for water of mammalian skin, especially the epidermis and more especially the 3
  • stratum corneum of mammalian skin by applying topically a safe and effective amount of a skin care composition comprising:
  • vitamin B3 compound a dermatologically acceptable carrier for said vitamin B3 compound.
  • the present invention further relates to articles of manufacture comprising a skin care composition comprising from about 0.1% to about 40% of a vitamin B 3 compound in a package for said skin care composition in association with the information about and/or instructions on the use of vitamin B 3 compounds to improve skin moisturization or hydration
  • moisture Unless otherwise indicated, all percentages and ratios used herein are by weight of the total composition. All weight percentages, unless otherwise indicated, are on an actives weight basis. All measurements made are at approximately 25°C, unless otherwise designated.
  • moisture broadly mean treatment or prevention of dry, flaky, scaly, tight, itchy skin to yield a smoother, softer skin as perceived by visual and/or tactile and/or sensorial assessments.
  • the terms "adsorb” or “adsorption” broadly mean adsorption of water onto the skin, particularly onto the proteins of the epidermis and more particularly of the stratum corneum.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive skin appearance or feel benefit, including independently the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • the skin moisturizing compositions of the present invention can comprise, consist of, or consist essentially of the essential elements and limitations of the 4
  • compositions of the present invention comprise a safe and effective amount of a natural or synthetic vitamin B3 compound.
  • the compositions of the present invention preferably comprise from about 0.01% to about 50%, more preferably greater than 1% to about 50%, even more preferably greater than 2% to about 40%, and still more preferably greater than 5% to about 30%, most preferably greater than 10% to about 20%, of the vitamin B3 compound .
  • vitamin B3 compound means a compound having the formula:
  • R is - CO ⁇ H2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH2OH
  • nicotinyl alcohol i.e., nicotinyl alcohol
  • derivatives thereof i.e., nicotinyl alcohol
  • salts of any of the foregoing Exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • Suitable esters of nicotinic acid include nicotinic acid esters of C1-C22 . preferably Cj-Ci 6, more preferably Cj-Cg alcohols.
  • the alcohols are suitably straight-chain or branched chain, cyclic or acyclic, saturated or unsaturated (including aromatic), and substituted or unsubstituted.
  • the esters are preferably non- rubifacient.
  • non-rubifacient means that the ester does not commonly yield a visible flushing response after application to the skin in the subject compositions (the majority of the general population would not experience a visible flushing response, although such compounds may cause vasodilation not visible to the naked eye).
  • a nicotinic acid material which is rubifacient at higher doses could be used at a lower dose at which a rubifacient response does not occur. 5
  • Non-rubifacient esters of nicotinic acid include, but are not limited to, tocopherol nicotinate and inositol hexanicotinate; tocopherol nicotinate is preferred.
  • derivatives of the vitamin B3 compound are derivatives of niacinamide resulting from substitution of one or more of the amide group hydrogens.
  • Nonlimiting examples of derivatives of niacinamide useful herein include nicotinyl amino acids, derived, for example, from the reaction of an activated nicotinic acid compound (e.g., nicotinic acid azide or nicotinyl chloride) with an amino acid, and nicotinyl alcohol esters of organic carboxylic acids (e.g., Cl - C18).
  • Specific examples of such derivatives include nicotinuric acid and nicotinyl hydroxamic acid, which have the following chemical structures: nicotinuric acid: o o
  • nicotinyl alcohol esters include nicotinyl alcohol esters of the carboxylic acids salicylic acid, acetic acid, glycolic acid, palmitic acid and the like.
  • vitamin B3 compounds useful herein are 2- chloronicotinamide, 6-aminonicotinamide, 6-methylnicotinamide, n-methyl- nicotinamide, n,n-diethylnicotinamide, n-(hydroxymethyl)-nicotinamide, quinolinic acid imide, nicotinanilide, n-benzylnicotinamide, n-ethylnicotinamide, nifenazone, nicotinaldehyde, isonicotinic acid, methyl isonicotinic acid, thionicotinamide, nialamide, l-(3-pyridylmethyl) urea, 2-mercaptonicotinic acid, nicomol, and n
  • vitamin B3 compounds may be used herein.
  • Preferred vitamin B3 compounds may be used herein.
  • B3 compounds are niacinamide and tocopherol nicotinate. Niacinamide is more preferred.
  • salts, derivatives, and salt derivatives of niacinamide are preferably those having substantially the same efficacy as niacinamide in the methods of regulating skin condition described herein.
  • Salts of the vitamin B3 compound are also useful herein.
  • Nonlimiting examples of salts of the vitamin B3 compound useful herein include organic or inorganic salts, such as inorganic salts with anionic inorganic species (e.g., chloride, bromide, iodide, carbonate, preferably chloride), and organic carboxylic acid salts (including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such as acetate).
  • anionic inorganic species e.g., chloride, bromide, iodide, carbonate, preferably chloride
  • organic carboxylic acid salts including mono-, di- and tri- Cl - C18 carboxylic acid salts, e.g., acetate, salicylate, glycolate, lactate, malate, citrate, preferably monocarboxylic acid salts such
  • Wenner "The Reaction of L- Ascorbic and D-Isoascorbic Acid with Nicotinic Acid and Its Amide", J. Organic Chemistry, VOL. 14, 22-26 (1949), which is incorporated herein by reference. Wenner describes the synthesis of the ascorbic acid salt of niacinamide.
  • the ring nitrogen of the vitamin B3 compound is substantially chemically free (e.g., unbound and/or unhindered), or after delivery to the skin becomes substantially chemically free ("chemically free” is hereinafter alternatively referred to as "uncomplexed”). More preferably, the vitamin B3 compound is essentially uncomplexed.
  • such complex is preferably substantially reversible, more preferably essentially reversible, upon delivery of the composition to the skin.
  • such complex should be substantially reversible at a pH of from about 5.0 to about 6.0. Such reversibility can be readily determined by one having ordinary skill in the art. 7
  • the vitamin B3 compound is substantially uncomplexed in the composition prior to delivery to the skin.
  • Exemplary approaches to minimizing or preventing the formation of undesirable complexes include omission of materials which form substantially irreversible or other complexes with the vitamin B3 compound, pH adjustment, ionic strength adjustment, the use of surfactants, and formulating wherein the vitamin B3 compound and materials which complex therewith are in different phases. Such approaches are well within the level of ordinary skill in the art.
  • the vitamin B3 compound contains a limited amount of the salt form and is more preferably substantially free of salts of a vitamin B3 compound.
  • the vitamin B3 compound contains less than about 50% of such salt, and is more preferably essentially free of the salt form.
  • the vitamin B3 compound in the compositions hereof having a pH of from about 4 to about 7 typically contain less than about 50% of the salt form.
  • the vitamin B3 compound may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the vitamin B3 compound is preferably substantially pure, more preferably essentially pure.
  • vitamin B 3 compounds increase skin moisturization or hydration by several different mechanisms.
  • Natural moisturizing factors include the water-binding, metabolic byproducts of skin proteins, especially filaggrin.
  • vitamin B 3 compounds increase the level of the above mentioned skin proteins, thereby increasing the level of natural moisturizing factors and, thus, moisturization.
  • Another mechanism involves the effect of vitamin B 3 compounds on the level and/or molecular weight of keratin proteins in the stratum corneum. These proteins bind water and aid in providing flexibility to the corneum cell layer. Increased keratin level, thus, increases the concentration of moisture-binding proteins, resulting in improved skin moisturization.
  • the degree of skin moisturization attained is also related to the type 8
  • involucrin is a protein precursor to the stratum corneum cell envelop which encases the keratin proteins and natural moisturizing factors.
  • Desmosomal proteins are in close association with the stratum corneum cell envelop and aid in connecting the stratum corneum cells. Increased involucrin and the desmosomal protein levels augment and strengthen the corneum cell envelope, helping to retard the dehydration of the encased keratins and natural moisturizing factors and, thereby, improving skin moisturization.
  • Carrier is a protein precursor to the stratum corneum cell envelop which encases the keratin proteins and natural moisturizing factors.
  • Desmosomal proteins are in close association with the stratum corneum cell envelop and aid in connecting the stratum corneum cells.
  • Increased involucrin and the desmosomal protein levels augment and strengthen the corneum cell envelope, helping to retard the dehydration of the encased keratins and natural moisturizing factors and
  • a dermatologically acceptable carrier is a dermatologically acceptable carrier.
  • the phrase "dermatologically -acceptable carrier”, as used herein, means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with the actives of the present invention and any other components, and will not cause any untoward safety or toxicity concerns
  • a safe and effective amount of carrier is from about 50% to about 99.99%, preferably from about 99.9% to about 80%, more preferably from about 98% to about 90%, most preferably from about 95% to about 90% of the composition.
  • the carrier can be in a wide variety of forms.
  • emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil- in-water-in-silicone emulsions, are useful herein. These emulsions can cover a broad range of viscosities, e.g, from about 100 cps to about 200,000 cps. These emulsions can also be delivered in the form of sprays using either mechanical pump containers or pressurized aerosol containers using conventional propellants. These carriers can also be delivered in the form of a mousse.
  • Suitable topical carriers include anhydrous liquid solvents such as oils, alcohols, and silicones (e.g., mineral oil, ethanol, isopropanol, dimethicone, cyclomethicone, and the like); aqueous-based single phase liquid solvents (e.g., hydro-alcoholic solvent systems); and thickened versions of these anhydrous and aqueous-based single phase solvents (e.g., where the viscosity of the solvent has been increased to form a solid or semi-solid by the addition of 9
  • anhydrous liquid solvents such as oils, alcohols, and silicones (e.g., mineral oil, ethanol, isopropanol, dimethicone, cyclomethicone, and the like)
  • aqueous-based single phase liquid solvents e.g., hydro-alcoholic solvent systems
  • thickened versions of these anhydrous and aqueous-based single phase solvents e.g., where the viscosity of the solvent has been increased to form a
  • the carriers of the skin care compositions can comprise from about 50% to about 99% by weight of the compositions of the present invention, preferably from about 75% to about 99%, and most preferably from about 85% to about 95%.
  • Preferred cosmetically and/or pharmaceutically acceptable topical carriers include hydro-alcoholic systems and oil-in-water emulsions.
  • the carrier can comprise from about 0% to about 99% of ethanol, isopropanol, or mixtures thereof, and from about 1% to about 99% of water. More preferred is a carrier comprising from about 5% to about 60% of ethanol, isopropanol, or mixtures thereof, and from about 40% to about 95% of water.
  • a carrier comprising from about 20% to about 50% of ethanol, isopropanol, or mixtures thereof, and from about 50% to about 80% of water.
  • the carrier when the carrier is an oil-in-water emulsion, the carrier can include any of the common excipient ingredients for preparing these emulsions.
  • suitable carriers are found in U.S. Patent 5,605,894 to Blank et al., and, U.S. Patent 5,681,852 to Bissett, both of which are herein incorporated by reference in their entirety.
  • the moisturizing compositions of the present invention may optionally include a film-forming agent or substantivity enhancer.
  • the film-forming agent or substantivity enhancer of the present invention is, generally, an organic polymer or resin which is soluble in the carrier and which during carrier evaporation will form a relatively thin film on the skin, thereby enhancing the substantivity of the vitamin B 3 compound.
  • the film-forming agent or substantivity enhancer can be natural or synthetic. Suitable film-forming agents or substantivity enhancers include, but are not 10
  • polyvinyl alcohol ethyl cellulose, methoxy cellulose, hydroxyethyl cellulose, nitrocellulose, beegum, polyvinylpyrrolidone, vinylpyrrolidone/vinyl acetate copolymers, copolymers of eicosene and vinyl pyrrolidone (an example of which is available from GAF Chemical Corporation as Ganex.RTM.
  • V-220 vinyl acetate/unsaturated carboxylic acid copolymers, terpolymers of methyl methacrylate/stearyl methacrylate/dimethylaminoethyl methacrylate, terpolymers of vinyl acetate/allyl stearate/allyloxyacetic acid, and maleic anhydride/methyl vinyl ether copolymers such as those commercially referred to as "Gantrez AN" as well as the ethyl, isopropyl and butyl esters of these copolymers, and maleic anhydride/butyl vinyl ether copolymers.
  • Gantrez AN maleic anhydride/methyl vinyl ether copolymers
  • Plasticizing agents desirably are added to the composition to impart flexibility to the polymer film.
  • Suitable plasticizing agents include, but are not limited to, polyethylene glycol, polyoxyethylene propylene glycol, polyoxypropylene glycol, polyoxyethylene polyoxypropylene block copolymers, glycerin and various vegetable oils such as cottonseed oil, palm oil, rapeseed oil, sunflower oil, castor oil, and the like.
  • polyethylene glycol polyoxyethylene propylene glycol
  • polyoxypropylene glycol polyoxyethylene polyoxypropylene block copolymers
  • glycerin various vegetable oils such as cottonseed oil, palm oil, rapeseed oil, sunflower oil, castor oil, and the like.
  • Hydrophobic plasticizing agents such as the vegetable oils, tended to impede the rate of release of the active substance while the hydrophilic materials such as polyoxypropylene glycol, polyethylene glycols and polyoxyethylene tended to enhance the rate of release of the active substance from the film.
  • the moisturizing compositions of the present invention may optionally comprise additional skin actives.
  • skin actives include hydroxy acids such as salicylic acid; desquamatory agents such as zwitterionic surfactants; sunscreens such as 2-ethylhexyl-p-methoxycinnamate, 4,4'-t-butyl methoxydibenzoyl-methane, octocrylene, phenyl benzimidazole sulfonic acid; sunblocks such as zinc oxide and titanium dioxide; anti-inflammatory agents; anti- oxidants/radical scavengers such as tocopherol and esters thereof; metal chelators, especially iron chelators; retinoids such as retinol, retinyl palmitate, retinyl acetate, retinyl propionate, and retinal; N-acetyl-L-cysteine and derivatives thereof; hydroxy acids such as glycolic acid; keto acids such as pyru, hydroxy
  • Preferred skin actives include hydroxy acids such as salicylic acid, sunscreen, antioxidants and mixtures thereof.
  • compositions of the present invention may also be included in the compositions of the present invention.
  • suitable additives or skin actives are discussed in
  • compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • Non-limiting examples of the product form can be a gel, emulsion, lotion, cream, liquid, solution, ointment, etc.
  • the methods of the present invention are useful for moisturizing or hydrating mammalian skin (especially human skin, especially human facial and body skin, more especially human hand, leg, and facial skin), especially the epidermis and more especially the stratum conreum of mammalian skin.
  • the skin moisturization or hydration methods of the present invention involve topically applying to the skin a safe and effective amount of the skin moisturizing or hydrating composition of the 12
  • the amount of the composition which is applied, the frequency of application and the period of use will vary widely depending upon the level of vitamin B3 compound and/or other components of a given composition and the level of moisturization or hydration desired.
  • the skin moisturizing or hydrating composition must be applied so as to provide a constant minimum vitamin B 3 concentration on the skin of from about 0.001 mg/cm2 to about 1 mg/cm2 .
  • the constant level can be achieved by reapplication of product to skin, especially to areas of the body which are often washed during the day, such as face and hands.
  • the composition is chronically applied (or reapplied such as after washing) to the skin.
  • chromenic topical application is meant continued topical application of the composition over an extended period during the subject's lifetime, preferably for a period of at least about one week, more preferably for a period of at least about two weeks, even more preferably for a period of at least one month, even more preferably for at least about three months, even more preferably for at least about six months, and more preferably still for at least about one year.
  • benefits are obtainable after various maximum periods of use (e.g., five, ten or twenty years)
  • it is preferred that chronic application continue throughout the subject's lifetime to maintain and/or increase the benefits achieved.
  • applications would be on the order of one to about four times per day over such extended periods, however application rates can be more than four times per day, especially for use on areas of the body which are often washed during the day, such as face and hands.
  • compositions of the present invention can be employed to provide a skin appearance and/or feel benefit.
  • Quantities of the present compositions which are typically applied per application are, in mg composition/cm ⁇ skin, from about 0.1 mg/cm ⁇ to about 10 mg/cm ⁇ .
  • amount is about 1 mg/cm ⁇ to about 4 mg/cm ⁇ , a more particularly useful application amount being about 2 mg/cm ⁇ .
  • Regulating skin condition is preferably practiced by applying a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave- on" composition).
  • a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave- on" composition).
  • a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave- on" composition).
  • the composition is preferably left on the skin for a period of at least about 5 minutes, more preferably at least about 20 minutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g., up to
  • the patch can be occlusive, semi-occlusive or non-occlusive.
  • the vitamin B3 compound composition can be contained within the patch or be applied to the skin prior to application of the patch.
  • the patch can also include additional actives such as chemical initiators for exothermic reactions such as those described in PCT application WO 9701313 to Burkett et al.
  • the patch is applied (e.g., to the face) at night as a form of night therapy.
  • compositions of the present invention are formed by combining and mixing the ingredients of each column using conventional technology and then applying to to the skin from about from about 0.5 g to about 50g.
  • Example 2 The following is an example of a skin cream inco ⁇ orating the compositions of the present invention.
  • the compositions are formed by combining and mixing the ingredients of each column using conventional technology and then applying to to the skin from about from about 0.5 g to about 50g.
  • compositions of the present invention are formed by combining and mixing the ingredients of each column using conventional technology and then applying to to the skin from about from about 0.5 g to about 50g. 16
  • PEG- 100 Stearate, ICI Americas Inc. , Wilmington, DE 10. Stearic acid, Henkel Co ⁇ ., Kankakee, IL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes permettant d'améliorer l'humidification et l'hydratation de la peau, et plus particulièrement, des méthodes qui améliorent la capacité d'absorption et/ou d'adsorption en eau de la peau.
PCT/US1999/005413 1998-03-16 1999-03-12 Compositions d'humidification de la peau WO1999047117A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002323101A CA2323101A1 (fr) 1998-03-16 1999-03-12 Compositions d'humidification de la peau
BR9907944-5A BR9907944A (pt) 1998-03-16 1999-03-12 Processos para adsorver água ou para absorver água na pele de um mamìfero, para umedecimento ou hidratação da pele de um mamìfero e artigo de manufatura
KR1020007010163A KR20010041868A (ko) 1998-03-16 1999-03-12 피부 보습 조성물
EP99911343A EP1063965A1 (fr) 1998-03-16 1999-03-12 Compositions d'humidification de la peau
AU30006/99A AU3000699A (en) 1998-03-16 1999-03-12 Skin moisturizing compositions
JP2000536357A JP2002506805A (ja) 1998-03-16 1999-03-12 保湿組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7813698P 1998-03-16 1998-03-16
US60/078,136 1998-03-16

Publications (1)

Publication Number Publication Date
WO1999047117A1 true WO1999047117A1 (fr) 1999-09-23

Family

ID=22142138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005413 WO1999047117A1 (fr) 1998-03-16 1999-03-12 Compositions d'humidification de la peau

Country Status (8)

Country Link
EP (1) EP1063965A1 (fr)
JP (1) JP2002506805A (fr)
KR (1) KR20010041868A (fr)
CN (1) CN1292680A (fr)
AU (1) AU3000699A (fr)
BR (1) BR9907944A (fr)
CA (1) CA2323101A1 (fr)
WO (1) WO1999047117A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20011491U1 (de) 2000-06-30 2000-10-12 Kampffmeyer Mühlen GmbH, 21107 Hamburg Hautpflegemittel
JP2002302444A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 乾燥による皮膚傷害の抑制剤もしくは修復剤
WO2002092070A1 (fr) * 2001-05-11 2002-11-21 Elan Corporation, Plc Sels d'acide isostearique utilises comme accelerateurs de permeation
KR20020088004A (ko) * 2001-05-07 2002-11-25 박종문 수세미 성분과 비타민을 이용한 피부미용 화장품 조성물
KR100581374B1 (ko) * 1999-04-22 2006-05-24 주식회사 엘지생활건강 칙칙한 피부 색상 개선에 효과를 가지는 화장료 조성물
EP1698320A1 (fr) * 2003-12-25 2006-09-06 Calpis Co., Ltd. Agent hydratant pour l'epiderme s'administrant par voie orale, produits alimentaires et boissons fonctionnels
WO2015074082A1 (fr) * 2013-11-18 2015-05-21 Polyremedy, Inc. Administration de matériaux thérapeutiques dermiques à base de micelles

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006241095A (ja) * 2005-03-04 2006-09-14 National Univ Corp Shizuoka Univ フィラグリン合成促進剤および紫外線傷害緩和剤
EP2742942B1 (fr) 2012-12-14 2019-05-22 Unilever N.V. Niacinamide pour induire la production de peptides antimicrobiens
KR101909594B1 (ko) * 2016-08-18 2018-10-18 (주)진셀팜 관음죽 및 인도 고무나무 추출물을 유효성분으로 함유하는 중금속 또는 미세먼지 제거용 화장료 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62123106A (ja) * 1985-11-22 1987-06-04 Kanebo Ltd 皮膚化粧料
JPS62126106A (ja) * 1985-11-26 1987-06-08 Kanebo Ltd 皮膚化粧料
JPS62138410A (ja) * 1985-12-10 1987-06-22 Kanebo Ltd 皮膚化粧料
WO1997039733A1 (fr) * 1996-04-23 1997-10-30 The Procter & Gamble Company Methodes de traitement et d'amelioration de l'aspect de la peau au moyen d'un compose a la vitamine b¿3?

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62123106A (ja) * 1985-11-22 1987-06-04 Kanebo Ltd 皮膚化粧料
JPS62126106A (ja) * 1985-11-26 1987-06-08 Kanebo Ltd 皮膚化粧料
JPS62138410A (ja) * 1985-12-10 1987-06-22 Kanebo Ltd 皮膚化粧料
WO1997039733A1 (fr) * 1996-04-23 1997-10-30 The Procter & Gamble Company Methodes de traitement et d'amelioration de l'aspect de la peau au moyen d'un compose a la vitamine b¿3?

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 11, no. 349 (C - 456) 14 November 1987 (1987-11-14) *
PATENT ABSTRACTS OF JAPAN vol. 11, no. 353 (C - 457) 18 November 1987 (1987-11-18) *
PATENT ABSTRACTS OF JAPAN vol. 11, no. 365 (C - 460) 27 November 1987 (1987-11-27) *
WENNINGER AND MCEVEN: "International Cosmetic Ingredient Dictionary and Handbook. Volume 1", 1997, THE COSMETIC, TOILETRY AND FRAGRANCE ASSOCIATION, WASHINGTON, DC USA, XP002103086 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100581374B1 (ko) * 1999-04-22 2006-05-24 주식회사 엘지생활건강 칙칙한 피부 색상 개선에 효과를 가지는 화장료 조성물
DE20011491U1 (de) 2000-06-30 2000-10-12 Kampffmeyer Mühlen GmbH, 21107 Hamburg Hautpflegemittel
JP2002302444A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 乾燥による皮膚傷害の抑制剤もしくは修復剤
JP4540872B2 (ja) * 2001-04-02 2010-09-08 株式会社資生堂 乾燥による皮膚傷害の抑制剤もしくは修復剤
KR20020088004A (ko) * 2001-05-07 2002-11-25 박종문 수세미 성분과 비타민을 이용한 피부미용 화장품 조성물
WO2002092070A1 (fr) * 2001-05-11 2002-11-21 Elan Corporation, Plc Sels d'acide isostearique utilises comme accelerateurs de permeation
EP1698320A1 (fr) * 2003-12-25 2006-09-06 Calpis Co., Ltd. Agent hydratant pour l'epiderme s'administrant par voie orale, produits alimentaires et boissons fonctionnels
EP1698320A4 (fr) * 2003-12-25 2009-02-18 Calpis Co Ltd Agent hydratant pour l'epiderme s'administrant par voie orale, produits alimentaires et boissons fonctionnels
WO2015074082A1 (fr) * 2013-11-18 2015-05-21 Polyremedy, Inc. Administration de matériaux thérapeutiques dermiques à base de micelles

Also Published As

Publication number Publication date
JP2002506805A (ja) 2002-03-05
CA2323101A1 (fr) 1999-09-23
EP1063965A1 (fr) 2001-01-03
BR9907944A (pt) 2000-10-24
KR20010041868A (ko) 2001-05-25
AU3000699A (en) 1999-10-11
CN1292680A (zh) 2001-04-25

Similar Documents

Publication Publication Date Title
KR100357848B1 (ko) 비타민비3화합물을포함하는피부외관을조절하기위한국소용조성물
US5962482A (en) Method of reducing cellulite in mamalian skin
US6238678B1 (en) Methods of regulating skin appearance with vitamin B3 compound
AU735384B2 (en) Compositions for regulating skin appearance
JPH1087476A (ja) ヒドロキシ酸またはレチノイドを含有する組成物中の刺激防止剤としてのルリヂサ種子油
EP0986368A1 (fr) Compositions pour soins cutanes
EP1063994A1 (fr) Methode de traitement des irritations de la peau
EP1063965A1 (fr) Compositions d'humidification de la peau
EP1063964A1 (fr) Compositions d'hydratation
WO1999047116A1 (fr) Compositions de soins pour la peau
WO1999047115A1 (fr) Compositions pour soins de la peau
MXPA00009057A (en) Skin moisturizing compositions
WO2000012059A1 (fr) Attenuation de l'irritation liee aux compositions a base de vitamine b3
CZ20003298A3 (cs) Prostředky pro zvlhčování kůže
US20230390178A1 (en) Skin Care Compositions and Methods of Use
MXPA00009056A (en) Method of treating skin irritation
CZ20002862A3 (cs) Prostředek pro místní aplikaciProstředek pro místní aplikaciProstředek pro místní aplikaci
MXPA00009144A (en) Compositions for regulating skin appearance
MXPA00009142A (en) Moisturizing compositions
MXPA99010843A (en) Skin care compositions
MXPA99009325A (en) Composition to enhance permeation of topical skin agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99803681.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2323101

Country of ref document: CA

Ref document number: 2323101

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-3298

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 536357

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009057

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 30006/99

Country of ref document: AU

Ref document number: 1020007010163

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999911343

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2000-3298

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1999911343

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007010163

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999911343

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-3298

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020007010163

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载